Netflix R&D increased by 7.8% to $959.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.6%, from $822.82M to $959.70M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 10.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $537.32M | $563.89M | $647.47M | $657.53M | $716.85M | $662.74M | $673.93M | $687.28M | $657.98M | $657.16M | $673.34M | $702.47M | $711.25M | $735.06M | $776.51M | $822.82M | $824.68M | $853.58M | $890.30M | $959.70M |
| QoQ Change | — | +4.9% | +14.8% | +1.6% | +9.0% | -7.5% | +1.7% | +2.0% | -4.3% | -0.1% | +2.5% | +4.3% | +1.3% | +3.3% | +5.6% | +6.0% | +0.2% | +3.5% | +4.3% | +7.8% |
| YoY Change | — | — | — | — | +33.4% | +17.5% | +4.1% | +4.5% | -8.2% | -0.8% | -0.1% | +2.2% | +8.1% | +11.9% | +15.3% | +17.1% | +15.9% | +16.1% | +14.7% | +16.6% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $822.82M | $824.68M | $853.58M | $890.30M | $959.70M |
| Total | $822.82M | $824.68M | $853.58M | $890.30M | $959.70M |